We analyzed the outpatient otologic surgery experience at our institution to identify those factors that are associated with a high risk ofpostoperative complications that require an unplanned hospital admission. Wefound that among a group of 662 patients who underwent group II oto logi c procedures (i .e., tympanoplasty with or without mastoidectomy, stapedotomy, and middle ear explo ration), the overall admission rate wa s 4.7%, ofwhicn 3.9% were unplanned. A significantly larger pereentage of children were admitted than adults (5.7 vs. 2.3 %), p rimarily for nausea and vomiting. Three fa ctors were sig nificantly associated with unplanned admissions: the type of surgery (tympanomastoidectomy with ossicular reconstruction), the duration ofgen eral an esthesia (>2 hr) , and asthma as a coexisting condition. The choice of antiemetic administered (ondansetron or droperidol) and the spe cific ag ents usedfor gene ral an esthesia did not appear to have any significant impact on unplanned admissions. We recommend that the thr ee predisposing fa ctors be taken into consideration when formulatin g the treatment plan. Scheduling an inpatient procedure for patients who hav e riskfactors for complications requiring hospitalization would avoid the ex tra costs and stress associated with unplanned admissions.
Introduction
The past decade has seen the widespread growth and acceptance of outpatient otologic surgery in the United States . The advent of effective antiemetics and sho rtaeting anesthetic agent s has significantly reduced the incidenee of postoperative nausea and vomiting. Moreover, improvements in pre-and perioperative instruction have made it possible for patients to better manage their own care after surgery. Finally, postoperative resu lts with regard to hearing and graft -take have been shown to be similar to outcomes following hospital inpa tient procedures .' From a financial standpoint, outpatient otologic surgery, of course , is cost-effective, and mos t third -party payers provide incentives to eneourage the use of amb ulatory surgery. This , in turn, has led to a proliferation of freestanding outpatient surgery centers that have peripheral associations with inpatient faci lities . However, not all freestanding surgery centers have inpatient facilities available, so some patients who req uire an unplan ned admission as aresult of postoperative complications of anesthes ia or surgery must be transferred to another facility . This only adds to the inconvenience and stress for both patient and family. Thus, two ques tions arise : J. Is it possible to identify whi cli patient characteristics or surgical int erventions are associated with a high risk of admission so that these patients can be treated in a ho spital setting initially? 2. Can we identify wh icli antiemetic and anesthetic agents are associated w ith the lowest risk ofpostoperative complications ?
We analyzed the outpatient otologic surgery experience at the University of Arkansas for Medical Sciences (UAMS) and its affiliate, the Arkansas Children's Hospital, a large pedi atric tertiary care center, both in Little Rock. Our aim was to identify any factors that are associated with a high risk of postoperative complications that require admission. By identifying pre-and perioperative par ameters associated with unplanned admissions, we can better facilitate patient care in an outpatient setting.
Materjals and methods
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There was onlyone unplanned admission for a patient who received local anesthesia. An adult who had undergone revision stapes surgery was admitted for vertigo, nausea, and vomiting.
Control-group comparison,
We compared the perioperative parameters of the 26 patients who had unplanned admissions with those of 26 age-matched controIs who were not admitted (table 3) . Statistically significant differences between the two groups were seen with respeet to the type of surgery, the duration of anesthesia, and the presence of asthma as a medical comorbidity (p<0.05 for each). Patients who underwent a tympanomastoidectomy with ossicular reconstruction and those or without mastoidectomy, stapedotomy, and middle ear exploration.? All surgeries were performed by the senior author and residents at UAMS or Arkansas Children' s Hospita!. We identified all patients who had either planned or unplanned Type I tympanoplasty admissions, and we compared the latter with an Tympanomastoidectomy age-matched control group consisting of patients with ossicular reconstruction who were not admitted. The following informa-Ossicular reconstruction tion was extracted from each patient' s chart: age at the time of surgery, sex, type of surgery, anes-Stapedotomy thesia technique, duration of surgery, medical Tympanomastoidectomy comorbidities, and reason for admission.
The two types of anesthesia were local standby Total and general. Local standby anesthesia was used for all adult stapedotomies as weil as for selected adult tympanoplasties, depending on the wishes of the patient. It con sisted of propofol at a dose of I to 2 mg/kg , titrated to effect during the canal injections, with approximately 6 mI of 1% lidocaine with 1:100,000 epinephrine. Small doses offentanyl (251lg) were used as needed to relax the patient.
General anesthesia was administered to all other adults and to all children. Canal injections identical to those used in the local cases were administered to facilitate hemostasis . Induction was performed with either propofol (2 mg/ kg) or thiopental (4 to 5 mg/kg) in combination with fentanyl (50 to 100 ug) and succinylcholine (I to 2 mg/ kg) to facilitate intubation. Halothane was used during induction in younger children prior to establishing intravenous access. Anesthesia was maintained with either isoflurane, halothane, or desflurane in combination with a mixture of air, 02' and nitrous oxide at concentrations sufficient to maintain hemodynamic parameters. The choice of inhalational anesthesia was at the discretion of the anesthesiologist. Halothane and isoflurane were used at Arkansas Children's Hospital, and isoflurane and desflurane were used for adults at UAMS.
All patients were given antiemetic drugs prior to induction. In patients who were seen before 1995, droperidol (0.05 to 0.1 mg/kg) was given 10 minutes prior to induction and repeated as needed for nausea and vomiting in the postanesthesia care unit. This antiemetic regimen was altered in 1995, when patients began receiving ondansetron (0.05 mg/kg) 30 minutes prior to induction and as needed postoperatively, up to a total dose of 4 mg. 
Discussion
The results of outpatient group II otologic procedures with regard to hearing result, graft-take, and complications such as facial nerve injury and cerebral spinal fluid leaks have been shown to be no different from those of inpatient procedures.' Children vs. adults. Our overall rate of unplanned admissions (3.9%) was somewhat higher than that reported in the literature (0.4%) .' One reason for the difference might be that almost half of the procedures we performed were on children, all of whom received general anesthesia; their unplanned admission rate (5.7%) was more than twice that of adults (2.3%), one-third 1 hr 26 min* of whom were given local anesthesia. The unplanned admission rate for all the general anesthesia cases (adult and pediatric) was 3.8% ofthe entire population. Asthma. Another reason for the different admission rates between adult and pediatric patients was the presence of asthma . Of all the medical comorbidities we analyzed, only asthma was associated with a statistically significant difference in the rate of unplanned admissions (p<0.05) . Although the incidenee of asthma among the adults and children in this study was not significantly different, there was a greater prevalence in the pediatric group (nine children versus two adults) . Likewise, four children were admitted for pulmonary complications, a complication not reported in the adult group . The reason that medically controlled asthma is associated with a significantly higher rate of unplanned admission than other medical comorbidities is difficult to ascertain. It is interesting to note that of the 10 patients with a history of asthma who were admitted unexpectedly, only four were admitted for pulmonary complications; nausea and vomiting accounted for the other six unplanned admissions. It is possible that the history of asthma lowered the threshold for admission in this group and biased the personnel in the postanesthesia care unit toward conservative treatment. Unfortunately, this is difficult to document from the postoperative record. We have now initiated steps to closely monitor patients with asthma to document the actual reason for admission. This documentation will help us determine whether a planned admission should be considered for this subset of patients .
Nausea and vomiting. The primary complications of outpatient otologic surgery seem to be associated not so much with the surgical procedure itself, but with the anesthetic techniques used. In our study, as in others, nausea and vomiting were the most common reasons for unplanned admission. Nausea and vomiting might be more common after otologic surgical procedures (the t One unplanned admission foll owed local anesthesia. whose duration of anesthesia exceeded 2 hours had a significantly higher incidenee of postoperative nausea and vomiting and a significantly higher admission rate (p<0.05). (These two parameters are obviously related because tympanomastoidectomy is a more extensive group II procedure that typically requires at least 2 hours of anesthesia time.) The particular antiemetic or anesthetic agent administered did not have any demonstrable impact on the rate of unplanned admissions. Asthma was also associated with a significant risk for unplanned admission (p<0.05). Ten of the 12 patients with asthma had to be admitted following outpatient surgery-six for nausea and vomiting and four for pulmonary complications.
Other medical problems-such as diabetes, cardiovascular disease, and renal disease-were not associated with unplanned admissions. Of the five planned admissions, two were for cardiovascular monitoring because of a history ofheart disease, two were for obstructive pulmonary disease , and one was for asthma.
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incidenee has been reported to be as high as 50 %J) because otologic procedures might stimulate the vestibular labyrinth. Labyrinth stimulation activates the chemoreceptor trigger zane and can lead to emesis.
Certainly, the choice of an antiemetic and its effect on the unplanned admission rate was ofparamount interest in this study. From a theoretical standpoint, one would anticipate that ondansetron would be advantageous in the treatment of nausea and vom iting associated with otologic procedures because of its method of action." Ondansetron is thought to function centrally, possibly as a selective antagonist of the 5-HT J receptors in the chemoreceptor zane, directly reducing vestibular labyrinth-induced nausea and vorniting.' Droperidol, another effective antiemetic , inhibits dopaminergic receptors in the chemoreceptor trigger zane, although it does not always influence labyrinth-induced vomiting."
It is interesting to note that while the total number of admissions was small in both groups that received antiemetics, there was no significant difference in the rate of unplanned admissions between those who received droperidol and those who received ondansetron. This finding was seen previously in a prospective study comparing these two antiemetics and placebo.' While both antiemetics lowered the incidenee of nausea and vomiting to a greater degree than did placebo following routine otologic procedures, there was no difference between the two drugs themselves. The ramification of this finding has to do with cost-effectiveness. At our institution, ondansetron is 18 times more expensive than droperidol, a fact that must be considered when this and other studies find no significant advantage of ondansetron over droperidol.
These comparisons also substantiate the fact that the nausea and vomiting associated with otologic procedures might not be related to stimulation of the labyrinth by surgical manipulation, but to factors related to general anesthesia. This theory is supported by our data on stapes surgery. Although the labyrinth is directly violated by this surgery, there were no unplanned admissions following primary surgery, all of which were performed with local anesthesia. In fact, the type of anesthesia (local vs. general) used had a significant impact on the rate of unexpected admissions . Onlyone of the 112 patients who received local anesthesia was admitted, and this was because the patient experienced vertigo after revision stapes surgery, not because of any complication of the anesthetic. Therefore, the use of general anesthesia should be Reach More Patients. The Deda Extension -a simple but effective sa lu tio n .
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Th e spee ifie type of induetion or inhalational agent used for general anesthesia appeared to have no signifieant bearing on nausea and vomiting . There is some evidenee in the literature suggesting that the use of propofol as a maint enanee agent might reduee the incid enee of nausea after ear surgery,? but we were not able to make such an assessment beeause propofol was used only as an induetion agent.
Duration of anesthesia. The duration of anesthesia was sig nifiea ntly assoc iated with the rate of unpl anned admi ssio ns. The mean duration of anesthesia for those who had unp lanned admiss ions was 2 hours and 17 minu tes, compared with only 1 hour and 26 minute s for the controis. Earlier data reveal that general anesthesia that lasts longer than 2 hour s is associate d with a significant risk for nausea and vomiting," which correlates weil with the data from our study.
Type of procedure. The duration of anesthesia is, of course, dictated by the type of surgieal procedure performed. In our study, tymp anomastoidectomy with ossicular reconstruction was significantly associ ated with unplanned admi ssion. General anesthesia for this type of surgery typic ally lasts 2 to 2.5 hours , which is longer than that needed for any of the other procedures. The significance of this find ing cer tainly has implications for resident training, where the duration of all surgeries is typically longer. Therefor e, time management should be emphasized, especially for tymp anomastoid surgery, to reduce unneeessary admissions and costs.
